Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
mRNA-3745 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| SAD: mRNA-3745 | EXPERIMENTAL | Participants will receive a single intravenous (IV) dose of mRNA-3745 on Day 1 in an inpatient setting. Participants that are/have been enrolled in the study and receive an administration of mRNA-3745 may also enroll in one of the MAD cohorts. The first MAD dose must occur at least 21 days after the SAD dose. |
| MAD: mRNA-3745 | EXPERIMENTAL | Participants will receive multiple IV doses of mRNA-3745 in an inpatient setting. Participants will have the option to continue treatment in the OLE. |
| Name | Type | Description |
|---|---|---|
| mRNA-3745 | DRUG | Sterile frozen liquid dispersion for injection |
Inclusion Criteria: * Documented GSD1a with confirmation of biallelic gene encoding glucose-6-phosphatase-α (G6PC) mutations by genetic testing. * Absence of hospitalization for hypoglycemia in the 4 weeks prior to Screening Exclusion Criteria: * Solid organ transplant * Received gene therapy for...
mRNA-3745 is an investigational RNA therapy being developed by Moderna, Inc. for glycogen storage disease. It is designed as a messenger RNA-based treatment and is currently in Phase 1 clinical development. The program is focused on glycogen storage disease type 1a, a metabolic condition.
mRNA-3745 is being studied for the treatment of glycogen storage disease type 1a (GSD1a), a metabolic disorder. It is an investigational therapy and has not been approved for any indication. The Phase 1 trial enrolls adult and pediatric participants with GSD1a.
mRNA-3745 is being developed by Moderna, Inc., which trades on the Nasdaq under the ticker MRNA. Moderna is the sponsor of the clinical program evaluating the therapy in glycogen storage disease type 1a.
mRNA-3745 is in Phase 1 clinical development. It is an investigational therapy and has not been approved by the FDA or any other regulatory agency. The single Phase 1 trial is currently active but not recruiting participants.
mRNA-3745 is being evaluated in one Phase 1 trial, NCT05095727, titled A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage Disease Type 1a (GSD1a). The trial has an estimated enrollment of 15 participants and is active but not recruiting. It is conducted in the United States, Canada, France, Netherlands, Poland, and Spain.
mRNA-3745 is an RNA therapy, specifically a messenger RNA-based treatment. It is designed to address the underlying metabolic defect in glycogen storage disease type 1a. The therapy is being developed by Moderna, Inc. and is in Phase 1 testing.